Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for September 2011
September 1, 2011
- Viral therapy delivered intravenously goes to cancer tumour sites: study
- Pfizer Extends Tender Offer to Acquire Icagen, Inc.
- Dr. Reddy's, Pfizer Settle Lipitor Patent Lawsuit
- US Patent Expiries Unlikely to Be A Big Opportunity
- Bayer Healthcare to Acquire Pathway Medical Technologies
- OXiGENE Announces Restructuring to Focus Resources on Promising Earlier Stage Clinical Programs
- FTC Report Examines How Authorized Generics Affect the Pharmaceutical Market
- Do TV Ads Correcting Misleading Statements by Drug Companies Work?
September 2, 2011
- Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions
- Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment
- FDA Sends Pfizer Letter Regarding Online Resources Webpage of Lipitor Site
- FDA Commissioner Margaret A. Hamburg?s Statement on the Passing of Dr. Charles Edwards
- Pfizer's Expansion Plan Shows Mass. Magnet for Life Sciences
- AmerisourceBergen Acquires Premier Source
- U.S. Kid Vaccine Rate at Least 90 Percent
- PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
- VWR International, LLC Acquires INTERNATIONAL P.B.I. S.p.A.
September 6, 2011
- AmerisourceBergen Acquires IntrinsiQ, LLC
- Pathfinder, LLC and SyntheMed, Inc. Complete Merger
- Evotec and Roche Agree to Develop Compound That Could Slow the Progression of Alzheimer's Disease
- Pfizer Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering Period
- Addex Regains Rights to Parkinson's Drug Candidates from Merck
- Anacor and GlaxoSmithKline Amend and Expand R&D Collaboration
- Biogen Idec Fully Acquires Biogen Dompé Joint Ventures
- Astellas Pharma signs a license agreement with Evec for a fully-human antibody
- Novartis Fights Patent Rejection in Indian Court
- Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent
- Sanofi Announces New Long Term Objectives
- Dendreon Ends Provenge Agreement With GlaxoSmithKline
- Pharmasset Climbs After Study Result Released
- Adolor Corporation Announces Completion of Acquisition of Full Ownership of ENTEREG (alvimopan)
- Medicare Paying for Surgeries on Dead Patients?
- Mayo Clinic Study Finds Widespread Medical Resident Burnout and Debt
September 7, 2011
- GPhA Taps Ralph G. Neas as New President and Chief Executive Officer
- Mississippi wins $38M case against Sandoz
- Ex-Glaxo Exec Founds Growing Pharma Firm
- Eisai to Accelerate Late-Stage Clinical Development of New Drugs by Effectively Leveraging External Resources
- Statement on Fosamax (Alendronate Sodium) Product Liability Trial
- Whistleblower lawsuit accuses 3 drugmakers
- F-Star and Merck Serono to Collaborate in the Discovery and Development of Novel Targeted Biologics
- NIH Stroke Prevention Trial Has Immediate Implications for Clinical Practice
September 8, 2011
- Transdermal Delivery Market Predicted to Reach $31.5 Billion by 2015: PharmaLive Special Report
- Tumor Necrosis Factor-alpha (TNFα) Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria
- FDA Advisers Review Clot Drug
- Drug Firms' Relationships With Doctors Are Cooling
- Pfizer Completes Move of Research Unit to Massachusetts
- Ardea Agrees With FDA on Gout Drug Studies
- Brain Stent Treatment Should Not Be Used for Strokes, Study Says
- Renowned Chef Launches "Franklin's Family Fixin's" Offering Adults with Type 2 Diabetes and/or High Cholesterol a Healthy "Fix" to Traditional Family Recipes
September 9, 2011
- New Drugs Should Be Compared With Existing Treatments Before Approval, Say Experts
- Dendreon Announces Company Restructuring and Provides Update on Provenge
- 'Illiterate Persons Not to Be Used for Clinical Trials'
- Hospira Slips After Holding Investor Meeting
- Analyst Expects FDA OK for J&J
- Dendreon Laying Off 500
September 12, 2011
- Gilead Sciences Expansion in Foster City Grows
- Notice of Delay in Some Shipments of Kitasato Daiichi Sankyo Flu Vaccine
- GlaxoSmithKline and Amicus Therapeutics Commence Second Phase III Study of Amigal for Fabry disease
- TAK-875 Enters into Phase III Clinical Trials for the Treatment of Type 2 Diabetes in Japan
- So Who is Big Pharma Paying? This Website Will Tell You
September 13, 2011
- FDA Announces Changes in Drug Center?s Oncology Office
- More than $49 Million Recovered for PA Agencies in Drug Price Settlement with Pharmaceutical Company
- Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.
- Barry Manilow Urges Americans to "Get Back in Rhythm" and Learn About All the Health Risks of Atrial Fibrillation (AFib)
- Merck and BGI Establish Strategic Collaboration focused on Biomarkers and Genomic Technologies
- Older Pills Often Safer; Many Think New Is Better
- Lilly, Amylin Release New Analysis of Bydureon
- Supergen Changes Name to Astex Pharma After Deal
- Brooke Shields To Star In Movie Based On New London Eminent Domain Case
- Pharmacyclics Reports Greater 4Q Research Costs
- Novartis Increases Growth Potential Through Integration of Alcon
- Merck Provides Update on the IMPROVE-IT Trial
- Study Evaluates Intranasal Insulin Therapy for Adults With Mild Cognitive Impairment or Alzheimer Disease
- Lilly Plans $30 Million Attack on Diabetes
- ImpactRx Acquires TargetRx
September 14, 2011
- FDA Investigates Multistate Outbreak of Listeriosis
- J&J Veteran to Lead Boston Scientific
- Merck Statement on Gardasil
- Boston Scientific names new CEO
- Teva investing $19M in CureTech, aiding in R&D
- FDA Sends Warning Letter to Luitpold Pharmaceuticals
- Boston Scientific Names Michael F. Mahoney as Company President, Announces CEO Transition Plan
- ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox(R) (deferiprone) Approval
- Fatal Opioid Overdoses on Steep Incline Warns Waismann Method Medical Director
- Transcept Pharmaceuticals Announces Plan to Resubmit Intermezzo New Drug Application Following Meeting with the U.S. Food & Drug Administration
September 15, 2011
- Drugmakers Pay Millions to Idaho Physicians
- VBI Announces Acquisition of Epixis and its Innovative eVLP Vaccine Platform
- Progenics Pharmaceuticals Announces Strategic Focus on Oncology
- Vivus to Resubmit Qnexa to FDA
- Abbott Cutting 160 Jobs, 10 in N. Chicago
- Generex Provides Update on Spinout of Antigen Express
- Clinic Weaning Patients Off Xanax
- Transcept: FDA Won't Need New Sleep-Drug Studies
- SEC Charges Former Consulting Executive and Friend with Insider Trading Ahead of Biotech Takeovers
September 16, 2011
- FDA Drug Safety Communication: Abnormal Heart Rhythms May be Associated with Use of Zofran (ondansetron)
- Elan Names Two New Directors, Says Cooke Retires
- Zofran (ondansetron): Drug Safety Communication - Risk of Abnormal Heart Rhythms
- Penn Bioethicist Challenges Bachmann on Gardasil Remark
- TAK-438 Enters into Phase III Clinical Trials in Japan for the Treatment of Acid-related Diseases
- GlaxoSmithKline (GSK) and McLaren Group Announce Innovative Strategic Partnership
- Alkermes plc and Elan Corporation plc Announce Completion of Merger Between Alkermes, Inc. and Elan Drug Technologies
- A Win for Innovation: President Signs America Invents Act
September 19, 2011
- Merck Serono Acquires Rights to PI-2301 Program for Multiple Sclerosis
- Novartis Announces Arthritis Drug Study Results
- Recall of Oral Contraceptives Issued
- First Yaz Birth Control Injury Trial In State Court Scheduled To Commence In January 2012
- U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin Patent Litigation
- Astellas -Administration of Seasonal Flu Vaccine ASP7374 Completed in Phase I/II Clinical Trial
- Jefferies Analyst Upgrades Bristol-Myers to 'Buy'
September 20, 2011
- Ex-official Arrested over Swine Flu Vaccines
- Jazz Pharmaceuticals to Buy Azur Pharma
- Merck Tells Staff of Layoffs by End of October
- Valeant Pharmaceuticals Announces Second Request from the Federal Trade Commission in Connection with Pending Dermatology Acquisitions
- Appointment of Chief Executive Officer
- Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.
- Valeant Gets More Questions From U.S. Regulators on Dermatology Deal
- Bachmann Says Vaccine Retardation Claim Not Hers
- Boston Scientific Lines Up $20M Pay Package for New Leader
- Obama's Health Care Cuts Spread the Pain
- Lilly Steps Up Efforts to Improve Diversity in Clinical Trials
- Merger of Express Scripts and Medco Health Solutions Will Address the Bipartisan Mandate for Safer, More Affordable, Higher Quality Healthcare
September 21, 2011
- Tranzyme Names Former Roche Exec to Board
- Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and Orencia (abatacept)
- Bristol-Myers Signs Cancer Drug Development Deal
- Takeda -Launch of Liovel LD And Liovel HD in Japan - Fixed Dose Combination Tablet of Nesina and Actos for Treatment of Type 2 Diabetes
- Pfizer -Eliquis (Apixaban) Available in the UK for the Prevention of Blood Clots After Elective Hip Or Knee Replacement
- Mylan Announces Xeloda Settlement and License Agreement
- Pacific Biosciences of California Inc Files (8-K) Disclosing Costs Associated with Exit or Disposal Activities
- Closure of PG545 Phase 1a Clinical Trial
- Orexigen Revives Obesity Pill Rejected By FDA
September 22, 2011
- Momenta Sues 3 Drugmakers over Generic Lovenox
- Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure
- Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
- PhRMA Elects Two New Members to Board of Directors
- Health Canada Lets Bayer Resume Sales of Controversial Clotting Drug
- FDA: Over-the-Counter Asthma Inhalers Containing Chloroflouorocarbons (CFCs) Will No Longer Be Made or Sold After Dec. 31, 2011
- Boehringer Ingelheim - Viramune (Nevirapine) Prolonged-Release Once-Daily Formulation for the treatment of HIV-1 infection receives approval in the EU
- Watson Confirms Amphastar Patent Lawsuit
- Anchen Pharmaceuticals Would Copy Drug Vimovo
- European Medicines Agency (EMA) Confirms Positive Benefit-risk Balance for Multaq
- European Medicines Agency Recommends Restricting Use of Multaq
- PharmAthene Awarded 50% Profit Split on Worldwide Sales of Smallpox Antiviral Therapy by Delaware Chancery Court
September 23, 2011
- FDA: Over-the-counter Asthma Inhalers Containing chloroflouorocarbons (CFCs) Will no Longer be Made or Sold After Dec. 31, 2011
- Avandia MDL Judge Denies Avandia Statute of Limitations Motion to Dismiss
- Pertussis Booster for Those Age 65-Plus
- Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
- Study Shows Backdoor Dealing By Drug Firms
- Enzon Announces Reduction in Force to Align Operations with Research and Development Activities
- European Medicines Agency Finalises Review of Baxter's Dialysis Solutions
- European Medicines Agency Concludes That Benefit-Risk Balance of Revlimid Remains Positive
- European Medicines Agency Recommends Contraindications for Suppositories Containing Terpenic Derivatives
- Enzon to Lay Off Almost Half Its Employees
- Pharmathene Shares Rocket on Court Ruling
- Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical Trial
September 26, 2011
- Novartis Drug Afinitor Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
- Abbott Japan and Eisai Submit Application in Japan for Additional Indication of Humira(adalimumab), a Fully Human Anti-TNF-alpha Monoclonal Antibody, for Inhibition of Structural Damage of Joints in Rheumatoid Arthritis
- Novartis Ready to Shed Jobs to Keep Costs Low
- Drug in Limbo, Catch-22 for FDA
- Teva Solidifies Japanese Operations with Complete Buyout of Partner's Interest in Teva's Japanese Joint Venture
- Study of Zolinza (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet Primary Endpoint
- Teva to Buy Out Japanese Joint Venture Partner
- Regulatory Update: GlaxoSmithKline Receives Complete Response Letter from FDA for candidate meningococcal and Hib combination vaccine
- AMRI Receives FDA Notification on Proposed Corrective Actions
September 27, 2011
- FDA Drug Safety Communication: Safety Review Update on the Possible Increased Risk of Blood Clots with Birth Control Pills Containing drospirenone
- Drug Companies Pay $25 Million to Illinois Doctors
- Merck Names Cuong Viet Do as Chief Strategy Officer
- Amerisourcebergen Buying Theracom for $250M
- Feds Subpoena Cephalon Over Treanda Marketing
September 28, 2011
- Alcon Seeks City Incentives to Expand, Add 750 Jobs
- Some Pain Meds Riskier for Cardiac Patients Than Others, Study Suggests
- Atypical Antipsychotics Appear to Be Effective For Only Few Off-Label Uses
- Astellas Pharma Inc. Discontinues Development of Darexaban (YM150),an Oral Direct Factor Xa Inhibitor
- Teva Exec Says Cephalon Deal Still on Track
- Merck Publishes Innovation Brochure With Attractive Interactive Features
- AF Stat Releases Smartphone App to Illustrate Risks, Consequences and Management Strategies for Atrial Fibrillation
- Valeant's Cholesterol Drug Colesevelam Wins Health Canada Approval
- NeuroSearch Provides Update on the Huntexil Development Programme and Plans A Comprehensive Restructuring of the Company's Operations
- Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals
September 29, 2011
- Merck to Pay $1.5 Million Penalty for Environmental Violations at Two Pa. Pharmaceutical Plants
- The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online
- Chelsea Therapeutics asks FDA to approve Northera
- Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations
- CSL Biotherapies - Response to News Reports on FDA Inspections
- Monthly Roundup - September 2011
September 30, 2011
- Takeda Completes Acquisition and Names New CEO of Nycomed
- AstraZeneca Enters Into a Settlement Agreement with Handa Pharmaceuticals regarding U.S. SEROQUEL XR Patent Litigation
- Sanofi US launches healthFORWARD 2.0
- Array Says Drug Misses Statistical Significance
- AstraZeneca Settles Patent Case With Handa
